Does BCBS Michigan Cover Zepbound? Formulary, Appeals, and Exceptions

Blue Cross Blue Shield of Michigan does not cover Zepbound for weight loss on most of its commercial plans. The exclusion took effect January 1, 2025 and applies to fully insured large group plans and some self-funded employer plans. Members can appeal, and Michigan’s insurance regulator has ordered BCBSM to pay for Zepbound in several individual cases, but the standing policy is an exclusion.

What the Formulary Says

BCBSM’s 2026 Clinical Drug List and Preferred Drug List both state the insurer does not cover “glucagon-like peptide-agonist drugs used for weight loss, including Saxenda, Wegovy, and Zepbound for commercial members of fully insured large groups and some self-funded groups.”1Blue Cross Blue Shield of Michigan. Clinical Drug List – June 2026 Blue Care Network, BCBSM’s HMO affiliate, carries the same exclusion on its 2026 Custom Drug List.2Blue Cross Blue Shield of Michigan. Blue Care Network Custom Drug List 2026

Coverage ended January 1, 2025. Before that date, BCBSM covered Zepbound for weight loss under prior authorization rules that required members to be at least 18, have a BMI of 35 or higher, document six months of lifestyle modification, and enroll in the Teladoc Health weight management program.3Blue Cross Blue Shield of Michigan. Changes to Weight Loss Drugs for Commercial Members Affected members were notified in mid-2024 that coverage would end.4Michigan Department of Insurance and Financial Services. DIFS Order, File No. 238501-001

Which Plans Are Affected

The exclusion language targets “commercial members of fully insured large groups and some self-funded groups.” That covers most of BCBSM’s employer-sponsored book, but the details vary by plan type.

  • Fully insured large group plans. Zepbound is excluded. BCBSM sets the formulary and bears the insurance risk.
  • Self-funded (ASO) employer plans. The employer decides what to cover. A self-funded group that wants to include GLP-1 weight loss drugs can do so and may set its own prior authorization criteria. If you don’t know which category your employer plan falls into, ask HR.3Blue Cross Blue Shield of Michigan. Changes to Weight Loss Drugs for Commercial Members
  • MESSA plans. The Michigan Education Special Services Association, which covers many school employees, does not cover Zepbound for weight loss or other diagnoses such as sleep apnea.5MESSA. Weight Loss Medications
  • Individual and family (marketplace) plans. BCBSM sells individual plans with their own drug lists, and the available materials don’t confirm whether they carry the same exclusion. Check your specific plan’s drug list or call the number on your ID card.6Blue Cross Blue Shield of Michigan. Drug Lists – Individuals and Family Plans
  • Medicare Advantage. Federal rules generally prohibit Medicare Part D and Medicare Advantage plans from covering anti-obesity medications. Some Medicare Advantage plans may offer limited coverage when Zepbound is prescribed specifically for obstructive sleep apnea, but that coverage is not guaranteed. BCBSM’s Medicare Advantage formulary lists Mounjaro as a preferred brand for type 2 diabetes but does not list Zepbound.7Drugs.com. Does Medicare Cover Zepbound8Blue Cross Blue Shield of Michigan. Medicare Advantage Coverage Guide

Does the Sleep Apnea Approval Change Things

Zepbound received FDA approval in December 2024 for treating moderate-to-severe obstructive sleep apnea in adults with obesity, adding a second indication beyond weight management.9Eli Lilly. FDA Approves Zepbound for Obstructive Sleep Apnea Some members have tried to use that indication to get past the exclusion. BCBSM has denied those requests too.

In a June 2025 decision, Michigan’s Department of Insurance and Financial Services upheld BCBSM’s denial of Zepbound for a member whose doctor prescribed it for OSA. The insurer said the drug “is not covered for any conditions,” and the DIFS Director agreed, holding that because the drug list classifies Zepbound as “not covered,” the exclusion applies regardless of the clinical indication.10Michigan Department of Insurance and Financial Services. DIFS Order, File No. 236103-001 In an April 2025 case, another OSA-based request was denied because the clinical records did not adequately document moderate-to-severe sleep apnea.11Michigan Department of Insurance and Financial Services. DIFS Order, File No. 234378-001

Mounjaro Is Not a Workaround

Zepbound and Mounjaro are both tirzepatide, made by Eli Lilly. Mounjaro is indicated for type 2 diabetes; Zepbound is for weight management and OSA. BCBSM covers Mounjaro but restricts it to members with a type 2 diabetes diagnosis, defined by a hemoglobin A1c of at least 6.5%.12Michigan Department of Insurance and Financial Services. DIFS Order, File No. 240509-001 Sharing an active ingredient doesn’t get non-diabetic members Mounjaro coverage.

One narrow exception came in December 2025, when DIFS ordered BCBSM to cover Mounjaro for a patient with polycystic ovary syndrome. The Director ruled that Michigan law (MCL 500.3406q) requires coverage of FDA-approved drugs used off-label for “chronic and seriously debilitating” conditions when peer-reviewed medical evidence supports safety and effectiveness. An independent reviewer board-certified in endocrinology found tirzepatide was supported by clinical guidelines for managing weight in adults with PCOS, and the Director held that BCBSM’s internal criteria could not override the statute.12Michigan Department of Insurance and Financial Services. DIFS Order, File No. 240509-001

What Happens on Appeal

DIFS has reviewed several BCBSM Zepbound denials under the Patient’s Right to Independent Review Act. Outcomes have gone both ways, and the pattern is instructive.

When Members Won

  • February 2025 (File 231850). An independent reviewer found BCBSM incorrectly required the patient to lose at least 5% of body weight while still titrating up to the maximum dose. FDA labeling does not require discontinuation during titration. Zepbound was declared medically necessary and covered.13Michigan Department of Insurance and Financial Services. DIFS Order, File No. 231850-001
  • April 2025 (File 234012). An endocrinologist reviewer found BCBSM’s criteria were “not consistent with standard of care criteria” and that tirzepatide “can significantly reduce glycemic levels and improve insulin sensitivity, as well as reducing body weight by more than 20 percent.” DIFS ordered coverage of Zepbound 15 mg pens.14Michigan Department of Insurance and Financial Services. DIFS Order, File No. 234012-001
  • May 2025 (File 235323). The Director found BCBSM’s denial inconsistent with the member’s own benefit plan, because neither the plan booklet nor the drug list actually established Zepbound as excluded for that member as of January 1, 2025.15Michigan Department of Insurance and Financial Services. DIFS Order, File No. 235323-001
  • June 2025 (File 235993). The reviewer again found BCBSM’s clinical criteria out of step with the current standard of care and said the patient needed adequate time for titration before efficacy could be judged.16Michigan Department of Insurance and Financial Services. DIFS Order, File No. 235993-001

When Denials Were Upheld

  • August 2025 (File 238501). The plan explicitly excluded “lifestyle drugs (such as drugs to treat erectile dysfunction or weight loss).” The Director treated it as a contractual exclusion, not a medical necessity dispute.4Michigan Department of Insurance and Financial Services. DIFS Order, File No. 238501-001
  • November 2025 (File 240449). DIFS affirmed the denial as consistent with the plan’s exclusion of GLP-1 products used for weight loss.17Michigan Department of Insurance and Financial Services. DIFS Order, File No. 240449

Two things drive outcomes. First, the specific language of your benefit plan. Plans with a broad “lifestyle drug” or GLP-1 exclusion have generally been enforced as written. Plans without that clear exclusion, or where the exclusion wasn’t in place on the relevant date, have opened the door to coverage. Second, whether BCBSM’s clinical criteria match the standard of care. Reviewers have repeatedly overturned denials tied to titration-period weight loss thresholds that don’t reflect how the drug is actually used.

How to Appeal a Denial

  • Internal appeal. Go through BCBSM’s internal grievance process first. The insurer will issue a “final adverse determination” at the end of that step.14Michigan Department of Insurance and Financial Services. DIFS Order, File No. 234012-001
  • External review. If the internal appeal fails, request an external review within four months of the denial. Submit the denial letter, a completed external review form, and a doctor’s statement explaining why covered alternatives are ineffective and why Zepbound is medically necessary. An Independent Review Organization issues a decision within 72 hours.18Blue Cross Blue Shield of Michigan. External Drug Review
  • DIFS review. You can also seek review by the Michigan Department of Insurance and Financial Services under the Patient’s Right to Independent Review Act. DIFS assigns an independent medical reviewer, and the Director issues a binding order.
  • Judicial review. Either side may seek review in circuit court within 60 days of the DIFS order.14Michigan Department of Insurance and Financial Services. DIFS Order, File No. 234012-001

Documentation matters. Members who prevailed at DIFS typically submitted BMI and weight history, evidence of lifestyle modification (food diaries, exercise logs, app records), physician letters on medical necessity and comorbidities, and Teladoc Health summary reports where relevant.14Michigan Department of Insurance and Financial Services. DIFS Order, File No. 234012-001

Michigan has no state law requiring private insurers to cover anti-obesity medications, so the exclusion is legal on its face. What the regulatory record shows is that individual members sometimes secure coverage when their plan’s language or clinical circumstances support it. If you aren’t sure how the exclusion applies to your own coverage, call the customer service number on the back of your Blue Cross ID card and ask about your specific plan.